Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.64 |
| ▸ | DRD1 | P21728 | 3/20 | 0.64 |
| ▸ | DRD3 | P35462 | 3/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186671 | 0.89 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL7977689 | 0.89 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL3919536 | 0.89 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL8175607 | 0.89 | OPRM1 (0.78) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL7668121 | 0.81 | CHRM2 (0.83) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL7317034 | 0.80 | OPRM1 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL8176312 | 0.80 | OPRM1 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL2054235 | 0.79 | CYP2D6 (0.67) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL1502253 | 0.79 | CYP2D6 (0.65) | OPRM1CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL16448455 | 0.78 | OPRM1 (0.70) | OPRM1CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064494-A | Method for detecting p-chlorobenzhydryl piperazine in levocetirizine hydrochloride particles | 康芝药业股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-116203156-B | Detection method of cetirizine oral liquid preparation related impurities | 北京柏雅联合药物研究所有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-110726788-B | Method for separating and measuring levocetirizine hydrochloride and related substances thereof by high performance liquid chromatography | 湖南九典制药股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-113848271-A | Method for detecting related substances in levocetirizine hydrochloride oral solution | 浙江核力欣健药业有限公司 | 2021-12-28 | — | — | CN | claimed |
| CN-110726788-A | Method for separating and measuring levocetirizine hydrochloride and related substances thereof by high performance liquid chromatography | 湖南九典制药股份有限公司 | 2020-01-24 | — | — | CN | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| US-20090325975-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20060258684-A1 | 2-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as anti-allergenic compound and process for its production | WOCKHARDT LIMITED (IN) | 2006-11-16 | — | — | US | claimed |
| EP-1628964-A1 | 2-[2-[4-[(4-CHLOROPHENYL) PHENYLMETHYL] -1-PIPERAZINYL] ETHOXY] ACETIC ACID MONOHYDROCHLORIDE AS ANTI-ALLERGENIC COMPOUND AND PROCESS FOR ITS PRODUCTION | Wockhardt Limited (IN) | 2006-03-01 | — | — | EP | claimed |
| WO-2004103982-A1 | 2-[2-[4-[(4-CHLOROPHENYL) PHENYLMETHYL]-1-PIPERAZINYL]ETHOXY]ACETIC ACID MONOHYDROCHLORIDE AS ANTI-ALLERGENIC COMPOUND AND PROCESS FOR ITS PRODUCTION | WOCKHARDT LIMITED (US) | 2004-12-02 | — | — | WO | claimed |
| CN-120064494-A | Method for detecting p-chlorobenzhydryl piperazine in levocetirizine hydrochloride particles | 康芝药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120064494-A | Method for detecting p-chlorobenzhydryl piperazine in levocetirizine hydrochloride particles | 康芝药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-4673684-A | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO CORPORATION (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258684-A1 | 2-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as anti-allergenic compound and process for its production | CMA1, HRH2, HRH1 | OPRM1 2829/4885CHRM2 280/4885ADRA2A 195/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885CHRM2 98/4885ADRA2A 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.